Medication-induced upper gastrointestinal tract injury

Journal of Clinical Pathology

Volumn 62, Issue 2, 2009, Pages 113-119

  Chen, Z ^a   Scudiere, J R ^b   Montgomery, E ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Harry and Jeanette Weinberg Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COLCHICINE; IRON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; POLYSTYRENESULFONATE SODIUM; SORBITOL;

APOPTOSIS; COLON NECROSIS; DIARRHEA; DIGESTIVE SYSTEM INJURY; ESOPHAGEAL EPITHELIAL NECROSIS; ESOPHAGITIS; ESOPHAGUS ULCER; GASTRITIS; GASTROINTESTINAL BIOPSY; HUMAN; INTESTINE NECROSIS; IRON THERAPY; MITOSIS INHIBITION; NECROSIS; NONHUMAN; PATHOLOGIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; SIDE EFFECT; ULCERATIVE ESOPHAGITIS; UPPER GASTROINTESTINAL TRACT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY; GASTROINTESTINAL DISEASES; HUMANS; IRON; MYCOPHENOLIC ACID; POLYSTYRENES; UPPER GASTROINTESTINAL TRACT;

EID: 61549115664     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.058263     Document Type: Review

References (44)

1. Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 2007;38:527-36.
2. Fabijanic D, Kardum D, Banic M, et al. [Nonsteroidal-anti- inflammatory drugs and serious undesirable gastrointestinal effects]. Lijec Vjesn 2007;129:205-13.
3. Go MF. Drug injury in the upper gastrointestinal tract: nonsteroidal anti-inflammatory drugs. Gastrointest Endosc Clin N Am 2006;16:83-97.
4. Holzer P. Role of visceral afferent neurons in mucosal inflammation and defense. Curr Opin Pharmacol 2007;7:563-9.
5. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008;135:41-60.
6. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
7. Abraham SC, Bhagavan BS, Lee LA, et al. Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. Am J Surg Pathol 2001;25:637-44.
8. Lillemoe KD, Romolo JL, Hamilton SR, et al. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery 1987;101:267-72.
9. Rashid A, Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol 1997;21:60-9.
10. Sherman A, Bini EJ. Pill-induced gastric injury. Am J Gastroenterol 1999;94:511-3.
11. Petersen KU, Jaspersen D. Medication-induced oesophageal disorders. Expert Opin Drug Saf 2003;2:495-507.
12. Scheiman JM. Prevention of NSAID-induced ulcers. Curr Treat Options Gastroenterol 2008;11:125-34.
13. Lanza FL. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treat Endocrinol 2002;1:37-43.
14. Jamieson J, Hinder RA, DeMeester TR, et al. Analysis of thirty-two patients with Schatzki's ring. Am J Surg 1989;158:563- 6.
15. Cortina G, Wren S, Armstrong B, et al. Clinical and pathologic overlap in nonsteroidal anti-inflammatory drug-related small bowel diaphragm disease and the neuromuscular and vascular hamartoma of the small bowel. Am J Surg Pathol 1999;23:1414-7.
16. Abid S, Mumtaz K, Jafri W, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005;37:740-1.
17. Haber MM, Lopez I. Reflux gastritis in gastroesophageal reflux disease: a histopathological study. Ann Diagn Pathol 1999;3:281-6.
18. Haber MM, Lopez I. Gastric histologic findings in patients with nonsteroidal anti-inflammatory drug-associated gastric ulcer. Mod Pathol 1999;12:592-8.
19. Abraham SC, Cruz-Correa M, Lee LA, et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999;12:1152-7.
20. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160:517-25.
21. Castell DO. ''Pill esophagitis''-the case of alendronate. N Engl J Med 1996;335:1058-9.
22. Colina RE, Smith M, Kikendall JW, et al. A new probable increasing cause of esophageal ulceration: alendronate. Am J Gastroenterol 1997;92:704-6.
23. Dobrucali A, Tobey NA, Awayda MS, et al. Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am J Physiol Gastrointest Liver Physiol 2002;283:G576-86.
24. Lanza FL. Bisphosphonates: oesophageal and gastric toxicity-fact or fiction. Ital J Gastroenterol Hepatol 1998;30:143-5.
25. Shakweh M, Bravo-Osuna I, Ponchel G. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. Eur J Pharm Sci 2007;31:262-70.
26. Pace F, Greco S, Pallotta S, et al. An uncommon cause of corrosive esophageal injury. World J Gastroenterol 2008;14:636-7.
27. Deng B, Wang RW, Jiang YG, et al. Prevention and management of complications after colon interposition for corrosive esophageal burns. Dis Esophagus 2008;21:57-62.
28. Dogan Y, Erkan T, Cokugras FC, etal. Caustic gastroesophageal lesions in childhood: an analysis of 473 cases. Clin Pediatr (Phila) 2006;45:435-8.
29. Kochhar R, Mehta SK, Nagi B, et al. Corrosive acid-induced esophageal intramural pseudodiverticulosis. A study of 14 patients. J Clin Gastroenterol 1991;13:371-5.
30. Kochhar R, Mittal BR, Kumar S, et al. Segmental and total oesophageal transit time in patients with corrosive-induced oesophageal stricture. Nucl Med Commun 2007;28:920-3.
31. Ramasamy K, Gumaste VV. Corrosive ingestion in adults. J Clin Gastroenterol 003;37:119-24.
32. Appelqvist P, Salmo M. Lye corrosion carcinoma of the esophagus: a review of 63 cases. Cancer 1980;45:2655-8.
33. Kochhar R, Sethy PK, Kochhar S, et al. Corrosive induced carcinoma of esophagus: report of three patients and review of literature. J Gastroenterol Hepatol 2006;21:777-80.
34. Purdy J, Appelman H, McKenna B. Sloughing esophagitis: a type of contact esophageal injury in debilitated patients? Mod Pathol 2008;21(1 Suppl 1):113A.
35. Abraham SC, Yardley JH, Wu TT. Erosive injury to the upper gastrointestinal tract in patients receiving iron medication: an underrecognized entity. Am J Surg Pathol 1999;23:1241-7.
36. Kaye P, Abdulla K, Wood J, et al. Iron-induced mucosal pathology of the upper gastrointestinal tract: a common finding in patients on oral iron therapy. Histopathology 2008;53:311-7.
37. Marginean EC, Bennick M, Cyczk J, et al. Gastric siderosis: patterns and significance. Am J Surg Pathol 2006;30:514-20.
38. Tenenbein M, Littman C, Stimpson RE. Gastrointestinal pathology in adult iron overdose. J Toxicol Clin Toxicol 1990;28:311-20.
39. Hruban RH, Yardley JH, Donehower RC, etal. Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 1989;63:1944- 50.
40. Daniels JA, Gibson MK, Xu L, et al. Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. Am J Surg Pathol 2008;32:473-7.
41. Berribi C, Loirat C, Jacqz-Aigrain E. Mycophenolate mofetil may induce apoptosis in duodenal villi. Pediatr Nephrol 2000;14:177-8.
42. Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 2003;11:295-302.
43. Papadimitriou JC, Drachenberg CB, Beskow CO, et al. Graft-versus-host diseaselike features in mycophenolate mofetil-related colitis. Transplant Proc 2001;33:2237-8.
44. Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol 2008;32:1367-72.